Summary
A randomised double-blind placebo-controlled crossover study evaluated the effects of zileuton 600mg 4 times daily on the pharmacokinetics of prednisolone after a single 40mg oral dose of prednisone. The effects of the single prednisone dose on the steady-state pharmacokinetics of zileuton were also evaluated.
Multiple doses of zileuton had no significant effects on mean peak plasma concentration (Cmax), time to Cmax(tmax), or area under the plasma concentrationtime curve from 0 to infinity (AUC0-∞) values for prednisolone after oral administration of prednisone 40mg. A slight but statistically significant increase in the mean half-life (t½) of prednisolone was detected with zileuton + prednisone administration compared with prednisone + placebo (from 2.8 to 2.9 hours); however, this change was of no clinical relevance.
Mean Cmax values of zileuton after coadministration with prednisone were similar to those of zileuton alone. While the single 40mg dose of prednisone resulted in a slight but statistically significant decrease in the mean zileuton AUC value from 0 to 6 hours (AUC0–6) [from 23 to 20 mg/L·h] and a reduction in tmax (from 2.3 to 1.7 hours), these results were not considered to be clinically significant.
Therefore, it is concluded that zileuton and prednisone may be coadministered with minimal risk of a clinically significant pharmacokinetic interaction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Carter GW, Young PR, Albert DH, et al. 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 1991; 256: 929–37
Samuelsson B, Dahlen S-E, Lindgren JA, et al. Leukotrienes and lipoxines: structures, biosynthesis and biological effects. Science 1987; 237: 1171–6
Brain SD, Williams TJ. Leukotrienes and inflammation. Pharmacol Ther 1990; 46: 57–66
Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to moderate-asthma. Ann Intern Med 1993; 119: 1059–66
Jenkins JS, Sampson PA. Conversion of cortisone to cortisol and prednisone to prednisolone. BMJ 1967; 2: 205–7
Meikle AW, Weed JA, Tyler FH. Kinetics and interconversion of prednisolone and prednisone studied with new immunoassays. J Clin Endocrinol Metab 1975; 41: 717–21
Jusko WJ, Rose JQ. Monitoring prednisone and prednisolone. Ther Drug Monit 1980; 2: 169–76
Granneman GR, Braeckman RA, Locke CS, et al. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet 1995; 29 Suppl. 2: 77–83
Locke CS. An exact confidence interval from untransformed data for the ratio of two formulation means. J Pharmacokinet Biopharm, 1984; 12(6): 649–55
Powell LW, Axelsen E. Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding. Gut 1972; 13: 690–6
Begg EJ, Atkinson HC, Gianarakis N. The pharmacokinetics of corticosteroid agents. Med J Aust 1987; 146: 37–41
Sirgo MA, Rocci Ml, Ferguson RK, et al. Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. Clin Pharmacol Ther 1985; 37: 534–8
Ferry JJ, Horvath AM, Bekersky I, Heath EC, et al. Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J Clin Pharmacol 1988; 28: 81–7
Awni WM, Braeckman RA, Granneman GR, et al. Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. Clin Pharmacokinet 1995; 29 Suppl. 2: 22–33
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Awni, W.M., Cavanaugh, J.H., Tzeng, TB. et al. Pharmacokinetic Interactions between Zileuton and Prednisone. Clin-Pharmacokinet 29 (Suppl 2), 105–111 (1995). https://doi.org/10.2165/00003088-199500292-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199500292-00015